Clinical Trial: Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Blinded, Randomized Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Measles-mumps-rubella-varicella Candidate Vaccine Given to Healthy Chil

Brief Summary: This is a study to evaluate the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals combined measles-mumps-rubella varicella candidate vaccine given to healthy children in their second year of life.

Detailed Summary: Separate injections of the licensed Priorix (MMR vaccine) and Varilrix (chickenpox vaccine) serve as control.
Sponsor: GlaxoSmithKline

Current Primary Outcome: Antibody levels after vaccination.

Original Primary Outcome: Same as current

Current Secondary Outcome: Safety of the study vaccines.

Original Secondary Outcome: Safety of the study vacccines

Information By: GlaxoSmithKline

Dates:
Date Received: August 4, 2005
Date Started: November 2005
Date Completion:
Last Updated: September 20, 2016
Last Verified: September 2016